Oral liquid medicine taste control method and system

Abstract

The invention relates to improvement of mouth feel of oral liquid medicine, and discloses a control method and system for mouth feel of oral liquid medicine, and the method comprises the following steps: identifying bitter components of oral liquid, determining the bitter component content of the bitter components, and constructing a mouth feel analysis model of the oral liquid; analyzing bitter chemical properties of the bitter components, determining ion exchange resin for adsorbing the bitter components, performing bitter adsorption on the oral liquid by using the ion exchange resin, determining a carrier material of the medicine components, calculating an optimal mixing ratio of the medicine components to the carrier material, and mixing the carrier material and the medicine components to obtain the oral liquid. Emulsifying the drug-carrier mixture and the oil phase, determining an external water phase of the water-in-oil primary emulsion, and constructing a water-in-oil-in-water multiple emulsion of the water-in-oil primary emulsion; curing the oil-in-water-in-oil-in-water multiple emulsion, separating the microcapsule-external water phase mixture, and mixing the oral liquid after adsorption with the medicine component microcapsules to obtain the target oral liquid. The mouth feel of the oral liquid medicine can be improved.

Description

Technical Field

[0001] The present invention relates to improving the taste of oral liquid medicine, and in particular to a method and system for controlling the taste of oral liquid medicine. Background Art

[0002] As a common drug dosage form, oral liquid usually contains active pharmaceutical ingredients, solvents (such as water or alcohol), and possible excipients (such as sweeteners, preservatives, pigments, etc.) to facilitate taking and digestion and absorption. The taste of the oral liquid directly affects the user's medication experience and compliance.

[0003] However, the existing oral liquid taste control technology mainly relies on methods such as adding flavoring agents and changing drug formulas. Although these methods can improve the taste to a certain extent, they often have problems such as poor taste correction effect and affect drug quality. Therefore, the development of a new oral liquid taste control technology is of great significance to improving users' medication experience and compliance. Summary of the invention

[0004] The present invention provides a method and system for controlling the taste of oral liquid medicine, the main purpose of which is to improve the taste of oral liquid medicine.

[0005] To achieve the above object, the present invention provides a method for controlling the taste of an oral liquid medicine, comprising:

[0006] Obtaining the oral liquid required by the target user and the taste requirements of the target user, identifying the bitter component of the oral liquid, determining the bitter component content of the bitter component, constructing a taste analysis model of the oral liquid based on the bitter component content and the taste requirements, and determining the bitterness value corresponding to the bitter component based on the taste analysis model;

[0007] Analyze the bitter chemical properties of the bitter component, determine the ion exchange resin used to adsorb the bitter component based on the bitter chemical properties, calculate the amount of resin added to the oral liquid using the bitter component content, and use the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the amount of resin added to obtain the adsorbed oral liquid;

[0008] Extracting target components from the oral liquid after adsorption to obtain drug components, determining carrier materials for the drug components, and calculating an optimal mixing ratio of the drug components and the carrier materials, and mixing the carrier materials and the drug components based on the optimal mixing ratio to obtain a drug-carrier mixture;

[0009] Identifying the oil phase of the drug-carrier mixture, emulsifying the drug-carrier mixture and the oil phase to obtain a water-in-oil colostrum, determining the external water phase of the water-in-oil colostrum, and constructing a water-in-oil-in-water multiple emulsion of the water-in-oil colostrum based on the external water phase;

[0010] A solidification environment of the water-in-oil-in-water emulsion is constructed, and based on the solidification environment, the water-in-oil-in-water emulsion is solidified to obtain a microcapsule-external aqueous phase mixture, the microcapsule-external aqueous phase mixture is separated to obtain drug component microcapsules, and the adsorbed oral liquid and the drug component microcapsules are mixed to obtain a target oral liquid.

[0011] Optionally, constructing a taste analysis model of the oral liquid based on the bitter component content and taste requirements includes:

[0012] Based on the taste requirement, analyzing the taste value of the oral liquid;

[0013] constructing an initial taste analysis model of the oral liquid according to the bitter component content and the taste value;

[0014] Acquiring experimental data of the initial taste analysis model, and training the taste analysis model based on the experimental data to obtain a trained taste analysis model;

[0015] The F1 score of the training taste analysis model is calculated, and when the F1 score meets a preset F1 score standard, the training taste analysis model is used as a taste analysis model.

[0016] Optionally, determining the ion exchange resin for adsorbing the bitter component based on the bitter chemical properties includes:

[0017] Based on the bitter chemical properties, identifying the bitter functional group of the bitter component;

[0018] determining a resin functional group for adsorbing the bitter functional group;

[0019] Determining the multiple ion exchange resins used for adsorbing the bitter components by means of the resin functional groups;

[0020] Testing the plurality of ion exchange resins to obtain exchange test results;

[0021] Analyzing resin test parameters of the plurality of ion exchange resins according to the exchange test results, wherein the resin test parameters include: exchange capacity, adsorption rate, and adsorption selectivity;

[0022] Analyzing the cost performance of the plurality of ion exchange resins based on the resin test parameters;

[0023] According to the cost performance ratio, an ion exchange resin of the plurality of ion exchange resins is determined.

[0024] Optionally, the calculating the amount of resin added to the oral liquid using the bitter component content includes:

[0025] Determining the adsorption environment of the oral liquid, wherein the adsorption environment includes: temperature, stirring time and stirring speed;

[0026] measuring the oral liquid volume of the oral liquid;

[0027] Based on the adsorption environment, analyzing the adsorption amount of the oral liquid corresponding to the ion exchange resin;

[0028] The amount of resin added to the oral liquid is calculated according to the adsorption amount, the volume of the oral liquid and the bitter component content.

[0029] Optionally, the carrier material for determining the drug component includes:

[0030] Analyzing the pharmacochemical properties and pharmacophysical properties of the drug ingredients;

[0031] determining the release time and release pattern of the drug component;

[0032] Determine the candidate carrier material of the drug component according to the drug chemical properties, drug physical properties, release time and release pattern;

[0033] identifying material properties of the candidate support material;

[0034] Testing the drug component and the candidate carrier material to obtain a drug-carrier mixture test result;

[0035] Based on the drug-carrier mixing test results, analyzing the influence of the candidate carrier material on the drug component;

[0036] Determine the stability and release behavior of the drug component in the candidate carrier material through the drug-carrier mixing test results;

[0037] The optimal carrier material among the candidate carrier materials is determined based on the characteristics, influence, stability and release behavior of the carrier material.

[0038] Optionally, the carrier material and the drug component are mixed based on the optimal mixing ratio to obtain a drug-carrier mixture, comprising:

[0039] measuring a pharmaceutical ingredient mass of the pharmaceutical ingredient;

[0040] configuring a carrier material mass of the carrier material based on the optimal mixing ratio;

[0041] Based on the mass of the drug component and the mass of the carrier material, the drug component and the carrier material are mixed by a preset mechanical stirring method to obtain an initial drug-carrier mixture;

[0042] Detecting the mixture quality of the initial drug-carrier mixture, wherein the mixture quality includes: mixture stability and mixture uniformity;

[0043] When the quality of the mixture meets the preset quality standard, the initial drug-carrier mixture is used as a drug-carrier mixture.

[0044] Optionally, the emulsifying the drug-carrier mixture and the oil phase to obtain water-in-oil colostrum comprises:

[0045] dissolving the drug-carrier mixture to obtain a mixture aqueous phase;

[0046] Constructing an emulsified environment of the water phase and the oil phase of the mixture, wherein the emulsified environment includes: emulsification temperature, emulsification time and emulsification stirring rate;

[0047] An emulsifier is provided for configuring the aqueous phase and the oil phase of the mixture;

[0048] According to the emulsification environment, the aqueous phase and the oil phase of the mixture are emulsified using the emulsifier to obtain an emulsified solution;

[0049] analyzing the emulsification effect of the emulsified solution;

[0050] When the emulsification effect meets the preset emulsification effect standard, the emulsified solution is extracted to obtain water-in-oil colostrum.

[0051] Optionally, analyzing the emulsification effect of the emulsified solution comprises:

[0052] measuring the dynamic viscosity of the emulsified solution;

[0053] Determining the temperature of the emulsified solution corresponding to the emulsification environment;

[0054] extracting spherical particles from the emulsified solution and measuring particle diameters of the spherical particles;

[0055] Calculating the particle diffusion coefficient of the emulsified solution according to the dynamic viscosity, temperature and particle diameter;

[0056] Determining the particle distribution of the emulsified solution based on the particle diffusion coefficient;

[0057] The emulsification stability of the emulsified solution is analyzed, and the emulsification effect of the emulsified solution is determined based on the emulsification stability and particle distribution.

[0058] Optionally, the step of constructing the water-in-oil-in-water multiple emulsion of the water-in-oil colostrum based on the external water phase comprises:

[0059] A stabilizer is provided for secondary emulsification of the water-in-oil colostrum and the external aqueous phase;

[0060] Based on the stabilizer, the water-in-oil colostrum and the external aqueous phase are secondary emulsified using a preset emulsification technology to obtain a double-emulsified solution;

[0061] Analyzing the particle encapsulation efficiency and drug release behavior of the emulsified solution;

[0062] Determining the emulsification performance of the emulsified solution based on the particle encapsulation efficiency and drug release behavior;

[0063] When the emulsion performance reaches the preset emulsion performance standard, the emulsion solution is extracted to obtain the water-in-oil-in-water emulsion.

[0064] In order to solve the above problems, the present invention also provides a control system for the taste of oral liquid medicine, the system comprising:

[0065] A target voltage requirement analysis module is used to obtain the application requirements of the plasma knife and determine the target voltage requirements required by the plasma knife based on the application requirements;

[0066] A bitterness analysis module, used to obtain the oral liquid required by the target user and the taste requirements of the target user, identify the bitter components of the oral liquid, determine the bitter component content of the bitter components, construct a taste analysis model of the oral liquid based on the bitter component content and taste requirements, and determine the bitterness value corresponding to the bitter component based on the taste analysis model;

[0067] A bitter adsorption module, used for analyzing the bitter chemical properties of the bitter component, determining the ion exchange resin used to adsorb the bitter component based on the bitter chemical properties, calculating the amount of resin added to the oral liquid using the bitter component content, and using the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the amount of resin added to obtain the adsorbed oral liquid;

[0068] A drug-carrier mixing module, used for extracting target components from the oral liquid after adsorption to obtain drug components, determining carrier materials for the drug components, and calculating an optimal mixing ratio of the drug components and the carrier materials, and mixing the carrier materials and the drug components based on the optimal mixing ratio to obtain a drug-carrier mixture;

[0069] a drug carrier emulsification module, for identifying the oil phase of the drug-carrier mixture, emulsifying the drug-carrier mixture and the oil phase to obtain a water-in-oil colostrum, determining the external water phase of the water-in-oil colostrum, and constructing a water-in-oil-in-water multiple emulsion of the water-in-oil colostrum based on the external water phase;

[0070] The target oral liquid preparation module is used to construct a solidification environment for the water-in-oil-in-water emulsion, solidify the water-in-oil-in-water emulsion based on the solidification environment to obtain a microcapsule-external aqueous phase mixture, separate the microcapsule-external aqueous phase mixture to obtain drug component microcapsules, and mix the adsorbed oral liquid and the drug component microcapsules to obtain the target oral liquid.

[0071] The embodiment of the present invention can adjust the taste of the oral liquid in a customized manner by obtaining the oral liquid required by the target user and the taste requirements of the target user, thereby improving the user's usage experience and satisfaction; optionally, the embodiment of the present invention can more accurately evaluate and adjust the content of the bitter component by determining the bitterness value corresponding to the bitter component based on the taste analysis model to achieve the best taste balance; the embodiment of the present invention can significantly reduce the bitterness in the oral liquid by using the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the amount of resin added, thereby improving the taste of the product and the compliance of the target user; the embodiment of the present invention can reduce the degradation and inactivation of the drug component and improve the stability of the drug by mixing the carrier material and the drug component based on the optimal mixing ratio to obtain a drug-carrier mixture; the embodiment of the present invention can improve the stability of the emulsion by determining the external water phase of the oil-in-water colostrum, and prevent problems such as stratification, flocculation and demulsification. Finally, the embodiment of the present invention can improve the taste of the final product by mixing the adsorbed oral liquid with the drug component microcapsules to obtain the target oral liquid, making it easier for the target user to accept. Therefore, the present invention can improve the taste of oral liquid medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1 A schematic flow chart of a method for controlling the taste of an oral liquid medicine provided in one embodiment of the present invention;

[0073] Figure 2 A functional module diagram of a control system for the taste of oral liquid medicine provided by an embodiment of the present invention;

[0074] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0075] It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention.

[0076] The embodiment of the present application provides a method for controlling the taste of an oral liquid medicine. The execution subject of the method for controlling the taste of the oral liquid medicine includes but is not limited to at least one of the electronic devices such as a server, a terminal, etc. that can be configured to execute the method provided in the embodiment of the present application. In other words, the method for controlling the taste of the oral liquid medicine can be executed by software or hardware installed on a terminal device or a server device, and the software can be a blockchain platform. The server includes but is not limited to: a single server, a server cluster, a cloud server or a cloud server cluster, etc. The server can be an independent server, or it can be a cloud server that provides basic cloud computing services such as cloud services, cloud databases, cloud computing, cloud functions, cloud storage, network services, cloud communications, middleware services, domain name services, security services, content delivery networks (Content Delivery Network, CDN), and big data and artificial intelligence platforms.

[0077] Reference Figure 1 FIG. 1 is a flow chart of a method for controlling the taste of oral liquid medicine provided by an embodiment of the present invention. In this embodiment, the method for controlling the taste of oral liquid medicine includes:

[0078] S1. Obtain the oral liquid required by the target user and the taste requirements of the target user, identify the bitter components of the oral liquid, determine the bitter component content of the bitter components, construct a taste analysis model of the oral liquid based on the bitter component content and taste requirements, and determine the bitterness value corresponding to the bitter component based on the taste analysis model.

[0079] The embodiment of the present invention can adjust the taste of the oral liquid in a customized manner by obtaining the oral liquid required by the target user and the taste requirements of the target user, thereby improving the user's usage experience and satisfaction. The taste requirements refer to the preferences and expectations of the target user for the taste, texture, smell, etc. of the oral liquid.

[0080] Optionally, as an embodiment of the present invention, the taste requirements of the target users may be obtained through market research.

[0081] The embodiment of the present invention can effectively solve the bitterness problem of oral liquid by identifying the bitter components of the oral liquid, thereby improving the compliance of target users. The bitter components refer to chemical substances in the oral liquid that can cause bitterness. These components may be bitter groups contained in the drug itself, impurities introduced during the production process of the drug, or byproducts produced by the interaction between the drug and the solvent or other components.

[0082] Optionally, as an embodiment of the present invention, the bitter components of the oral liquid can be identified by a gas chromatography-mass spectrometry method, wherein the gas chromatography-mass spectrometry refers to a method of separating volatile bitter components by gas chromatography and then determining their chemical structures by mass spectrometry analysis.

[0083] The embodiment of the present invention can provide a scientific basis for subsequent taste adjustment by determining the bitter component content of the bitter component. Wherein, the bitter component content refers to the concentration or amount of the bitter component in the oral liquid.

[0084] Optionally, as an embodiment of the present invention, the bitter component content of the bitter component can be confirmed by mass spectrometry, wherein the mass spectrometry is an analytical technique for determining the molecular mass and structure of a compound.

[0085] Furthermore, the present invention can predict the final taste by constructing a taste analysis model of the oral liquid based on the bitter component content and taste requirements, thereby optimizing the taste in the early stage of product development. The taste analysis model refers to a statistical model for predicting or simulating the taste characteristics of oral liquid.

[0086] As an embodiment of the present invention, the taste analysis model of the oral liquid is constructed based on the bitter component content and taste requirements, including:

[0087] Based on the taste requirement, analyzing the taste value of the oral liquid;

[0088] According to the bitter component content and taste value, the initial taste analysis model of the oral liquid was constructed using the following formula:

[0089]

[0090] Where K represents the taste value, g(H) represents the initial taste analysis model, and K max represents the maximum taste value in the taste value, e represents the exponential function with e as the base, H represents the bitter component content, a represents the maximum value corresponding to the bitter component content, b represents a constant, and n represents an exponential constant;

[0091] Acquiring experimental data of the initial taste analysis model, and training the taste analysis model based on the experimental data to obtain a trained taste analysis model;

[0092] The F1 score of the training taste analysis model is calculated, and when the F1 score meets a preset F1 score standard, the training taste analysis model is used as a taste analysis model.

[0093] Among them, the taste value is a quantitative representation of the taste characteristics of the oral liquid. The initial taste analysis model is an initial model constructed based on the bitter component content and the taste value to try to predict or simulate the taste characteristics of the oral liquid. The experimental data is a data set used to train and verify the initial taste analysis model, including the bitter component content and the corresponding taste value. The trained taste analysis model refers to a model after the initial model is adjusted and optimized using experimental data. The F1 score is an indicator to measure the performance of a binary classification model, which is the harmonic mean of accuracy and recall. The preset F1 score standard is a pre-set threshold used to determine whether the performance of the trained taste analysis model has reached an acceptable level.

[0094] Optionally, calculating the F1 score of the trained taste analysis model includes:

[0095] Obtaining the accuracy and recall rate of the trained taste analysis model;

[0096] Based on the accuracy and recall, the F1 score of the trained taste analysis model was calculated using the following formula:

[0097]

[0098] Among them, τ represents the F1 score, A represents the accuracy, and R represents the recall.

[0099] The accuracy refers to the proportion of all samples correctly classified by the trained taste analysis model, and the recall rate refers to the proportion of all positive samples correctly identified by the trained taste analysis model.

[0100] The embodiment of the present invention can more accurately evaluate and adjust the content of the bitter component by determining the bitterness value corresponding to the bitter component based on the taste analysis model to achieve the best taste balance. The bitterness value refers to a value used to reflect the concentration and intensity of the bitter component in the oral liquid.

[0101] S2. Analyze the bitter chemical properties of the bitter component, determine the ion exchange resin used to adsorb the bitter component based on the bitter chemical properties, and calculate the amount of resin added to the oral liquid using the bitter component content. Based on the bitterness value and the amount of resin added, use the ion exchange resin to adsorb the bitterness of the oral liquid to obtain the adsorbed oral liquid.

[0102] The embodiments of the present invention can help understand the biological and chemical mechanisms of bitterness by analyzing the bitter chemical properties of the bitter components, thereby providing a scientific basis for bitterness regulation. The bitter chemical properties refer to the molecular structure and chemical properties of the bitter components, which determine the bitterness intensity and properties of the bitter components.

[0103] Optionally, as an embodiment of the present invention, the analysis of the bitter chemical properties of the bitter components can be performed by a data analysis method, wherein the data analysis method includes: principal component analysis (PCA) and multivariate analysis of variance (MANOVA).

[0104] The embodiment of the present invention can improve the adsorption effect of bitter components by determining the ion exchange resin used to adsorb the bitter components based on the bitter chemical properties, thereby improving the taste of oral liquid. The ion exchange resin refers to a class of polymers with specific functional groups (such as carboxyl, amino, sulfonic acid, etc.), which can exchange with ions in the solution.

[0105] As an embodiment of the present invention, the step of determining the ion exchange resin for adsorbing the bitter component based on the bitter chemical properties includes:

[0106] Based on the bitter chemical properties, identifying the bitter functional group of the bitter component;

[0107] determining a resin functional group for adsorbing the bitter functional group;

[0108] Determining the multiple ion exchange resins used for adsorbing the bitter components by means of the resin functional groups;

[0109] Testing the plurality of ion exchange resins to obtain exchange test results;

[0110] Analyzing resin test parameters of the plurality of ion exchange resins according to the exchange test results, wherein the resin test parameters include: exchange capacity, adsorption rate, and adsorption selectivity;

[0111] Analyzing the cost performance of the plurality of ion exchange resins based on the resin test parameters;

[0112] According to the cost performance ratio, an ion exchange resin of the plurality of ion exchange resins is determined.

[0113] Among them, the bitter functional groups refer to specific chemical groups in bitter ingredients that are related to bitter perception. These functional groups interact with taste receptors to produce bitter perception. The resin functional groups refer to specific chemical groups existing on the surface or inside of ion exchange resins. These functional groups can interact with bitter functional groups to achieve adsorption of bitter ingredients. The multiple ion exchange resins refer to a collection of ion exchange resins with different chemical structures and performance parameters. The exchange test results refer to the test results obtained by testing multiple ion exchange resins under experimental conditions. The exchange capacity refers to the maximum number of ions that a resin can adsorb. The adsorption rate refers to the speed at which a resin adsorbs bitter ingredients. The adsorption selectivity refers to the relative strength of the resin's affinity for bitter ingredients and other ingredients.

[0114] Optionally, the resin test parameters of the plurality of ion exchange resins may be analyzed according to the exchange test results by a multivariate statistical analysis method, wherein the variable statistical analysis method includes principal component analysis, factor analysis, cluster analysis, and the like.

[0115] The embodiment of the present invention can accurately control the amount of resin added to the oral liquid by calculating the amount of resin added to the oral liquid using the bitter component content, thereby ensuring that the bitter components are effectively adsorbed and removed. The resin addition amount refers to the amount of ion exchange resin added to the oral liquid to adsorb and remove the bitter components.

[0116] As an embodiment of the present invention, the method of calculating the amount of resin added to the oral liquid using the bitter component content includes:

[0117] Determining the adsorption environment of the oral liquid, wherein the adsorption environment includes: temperature, stirring time and stirring speed;

[0118] measuring the oral liquid volume of the oral liquid;

[0119] Based on the adsorption environment, analyzing the adsorption amount of the oral liquid corresponding to the ion exchange resin;

[0120] According to the adsorption amount, oral liquid volume and bitter component content, the resin dosage of the oral liquid is calculated using the following formula:

[0121]

[0122] Among them, T m Indicates the amount of resin added, H k Indicates the bitter component content, Q v Indicates the volume of oral solution, X m Indicates the amount of adsorption.

[0123] Wherein, the temperature refers to the temperature of the oral liquid. Different temperatures will affect the adsorption performance and adsorption rate of the ion exchange resin. The stirring time refers to the length of time the oral liquid is stirred, which can fully allow the ion exchange resin to fully contact with the bitter components. The stirring speed refers to the stirring speed. A higher stirring speed can usually increase the contact frequency between the solute and the resin. The adsorption amount refers to the amount of bitter components in the oral liquid adsorbed by the ion exchange resin under a given adsorption environment.

[0124] Optionally, the analysis of the adsorption amount of the oral liquid corresponding to the ion exchange resin based on the adsorption environment can be performed by experimental methods, such as gravimetric analysis, colorimetry, HPLC, etc.

[0125] In the embodiment of the present invention, the bitterness of the oral liquid is adsorbed by the ion exchange resin based on the bitterness value and the amount of the resin, and the adsorbed oral liquid is obtained, which can significantly reduce the bitterness in the oral liquid and improve the taste of the product and the compliance of the target users. The adsorbed oral liquid refers to the oral liquid after the ion exchange resin adsorption process.

[0126] S3. Extracting target components from the oral liquid after adsorption to obtain drug components, determining the carrier material of the drug components, and calculating the optimal mixing ratio of the drug components and the carrier material; based on the optimal mixing ratio, mixing the carrier material and the drug components to obtain a drug-carrier mixture.

[0127] In the embodiment of the present invention, by extracting the target component from the oral liquid after adsorption, the drug component can be obtained to further improve the taste of the oral liquid and make it more palatable. The drug component refers to the main active ingredient contained in the oral liquid.

[0128] Optionally, as an embodiment of the present invention, the extraction of target components from the oral liquid after adsorption to obtain drug components can be performed by supercritical fluid extraction, wherein the supercritical fluid extraction refers to a technology that uses a fluid in a supercritical state as an extractant.

[0129] The embodiment of the present invention can mask or reduce the bad taste by determining the carrier material of the drug component, thereby improving the drug use experience of the target user. The carrier material refers to a high molecular polymer, natural or synthetic material used to encapsulate or attach the drug component, such as gelatin, gum arabic, and polylactic acid.

[0130] As an embodiment of the present invention, the carrier material for determining the drug component includes:

[0131] Analyzing the pharmacochemical properties and pharmacophysical properties of the drug ingredients;

[0132] determining the release time and release pattern of the drug component;

[0133] Determine the candidate carrier material of the drug component according to the drug chemical properties, drug physical properties, release time and release pattern;

[0134] identifying material properties of the candidate support material;

[0135] Testing the drug component and the candidate carrier material to obtain a drug-carrier mixture test result;

[0136] Based on the drug-carrier mixing test results, analyzing the influence of the candidate carrier material on the drug component;

[0137] Determine the stability and release behavior of the drug component in the candidate carrier material through the drug-carrier mixing test results;

[0138] The optimal carrier material among the candidate carrier materials is determined based on the characteristics, influence, stability and release behavior of the carrier material.

[0139] Among them, the drug chemical properties refer to the chemical properties of the drug, such as chemical composition, functional groups, molecular structure, solubility, stability, etc. The drug physical properties refer to the physical properties of the drug, such as physical state (such as solid, liquid, colloidal), particle size, density, solubility, viscosity, etc. The release time refers to the time required for the drug to be released in the carrier material, including: immediate release, short-term release or long-term sustained release. The release mode refers to the rate, duration, and control method (such as zero-order release, first-order release, pulse release, etc.) of drug release from the carrier material. The candidate carrier material refers to a set of carrier materials that meet the requirements in the process of determining the carrier material of the drug component. The material properties refer to the chemical properties, physical properties, biocompatibility, biodegradability, toxicity, stability, solubility, viscosity, etc. of the candidate carrier material. The drug-carrier mixing test result refers to the result obtained by testing after mixing the drug component with the candidate carrier material. The influence refers to the influence of the candidate carrier material on the chemical properties, physical properties, bioavailability, pharmacodynamics, etc. of the drug component. The stability refers to the stability of the drug component in the candidate carrier material, including chemical stability, physical stability and biological stability. The release behavior refers to the release characteristics of the drug component in the candidate carrier material, including the release rate, duration and control method.

[0140] The embodiments of the present invention can achieve control of the drug release rate and release pattern by calculating the optimal mixing ratio of the drug component and the carrier material, thereby achieving a sustained release or controlled release effect. The optimal mixing ratio refers to the most ideal ratio between the drug component and the carrier material determined by calculation and experimental testing.

[0141] Optionally, the calculation of the optimal mixing ratio of the drug component and the carrier material can be performed by constructing a mathematical model.

[0142] In the embodiment of the present invention, the carrier material and the drug component are mixed based on the optimal mixing ratio to obtain a drug-carrier mixture, which can reduce the degradation and inactivation of the drug component and improve the stability of the drug. The drug-carrier mixture refers to the compound formed by mixing the drug component with the carrier material.

[0143] As an embodiment of the present invention, the carrier material and the drug component are mixed based on the optimal mixing ratio to obtain a drug-carrier mixture, comprising:

[0144] measuring a pharmaceutical ingredient mass of the pharmaceutical ingredient;

[0145] configuring a carrier material mass of the carrier material based on the optimal mixing ratio;

[0146] Based on the mass of the drug component and the mass of the carrier material, the drug component and the carrier material are mixed by a preset mechanical stirring method to obtain an initial drug-carrier mixture;

[0147] Detecting the mixture quality of the initial drug-carrier mixture, wherein the mixture quality includes: mixture stability and mixture uniformity;

[0148] When the quality of the mixture meets the preset quality standard, the initial drug-carrier mixture is used as a drug-carrier mixture.

[0149] The preset mechanical stirring mode refers to the stirring device and its operating parameters used to mix the drug component and the carrier material, such as stirring speed, stirring time, stirring temperature, etc. The initial drug-carrier mixture refers to the initial mixture of the drug component and the carrier material obtained by mechanical stirring. The mixture stability refers to the physical and chemical stability of the mixture over a certain period of time. The mixture uniformity refers to the spatial distribution uniformity of the drug component and the carrier material in the mixture.

[0150] Optionally, the detection of the mixture quality of the initial drug-carrier mixture can be performed by a stability test experiment and a laser particle size analyzer.

[0151] S4. Identify the oil phase of the drug-carrier mixture, emulsify the drug-carrier mixture and the oil phase to obtain a water-in-oil colostrum, determine the external water phase of the water-in-oil colostrum, and construct a water-in-oil-in-water multiple emulsion of the water-in-oil colostrum based on the external water phase.

[0152] The embodiments of the present invention can improve the absorption and bioavailability of the drug in the body by identifying the oil phase of the drug-carrier mixture, ensuring that the drug is released and absorbed in an effective manner. The oil phase refers to the oil phase surrounding the inner water phase, which is usually composed of oily substances and can be vegetable oil, mineral oil or synthetic oil.

[0153] Optionally, the identification of the oil phase of the drug-carrier mixture can be performed by liquid chromatography analysis, wherein the liquid chromatography analysis refers to an analysis method for detecting volatile or non-volatile components in the oil phase.

[0154] In the embodiment of the present invention, the water-in-oil colostrum is obtained by emulsifying the drug-carrier mixture and the oil phase, which can mask the bad smell and taste of the drug and improve the medication experience and compliance of the target users. The water-in-oil colostrum refers to an emulsified system in which the oil phase is outside the inner water phase and surrounds the inner water phase.

[0155] As an embodiment of the present invention, the emulsifying the drug-carrier mixture and the oil phase to obtain water-in-oil colostrum comprises:

[0156] dissolving the drug-carrier mixture to obtain a mixture aqueous phase;

[0157] Constructing an emulsified environment of the water phase and the oil phase of the mixture, wherein the emulsified environment includes: emulsification temperature, emulsification time and emulsification stirring rate;

[0158] An emulsifier is provided for configuring the aqueous phase and the oil phase of the mixture;

[0159] According to the emulsification environment, the aqueous phase and the oil phase of the mixture are emulsified using the emulsifier to obtain an emulsified solution;

[0160] analyzing the emulsification effect of the emulsified solution;

[0161] When the emulsification effect meets the preset emulsification effect standard, the emulsified solution is extracted to obtain water-in-oil colostrum.

[0162] Wherein, the aqueous phase of the mixture refers to the solution formed by dissolving the drug-carrier mixture in water. The emulsification temperature refers to the temperature conditions when the emulsification operation is performed. The emulsification time refers to the time for the aqueous phase and the oil phase of the mixture to mix during the emulsification process. The emulsification stirring rate refers to the rotation speed of the stirrer or stirring device during the emulsification process. The emulsifier refers to a chemical substance used to reduce the oil-water interfacial tension and promote the mixing of the oil phase and the aqueous phase. The emulsified solution refers to a stable emulsion formed by mixing the aqueous phase and the oil phase of the drug-carrier mixture through the action of the emulsifier during the emulsification process. The emulsification effect refers to the stability, viscosity, particle size distribution and other characteristics of the emulsified solution. The preset emulsification effect standard refers to the index of the emulsification effect pre-set during the emulsification process.

[0163] Optionally, according to the emulsification environment, the emulsification of the aqueous phase and the oil phase of the mixture using the emulsifier can be performed by slowly adding the aqueous phase of the mixture into the oil phase while performing high-speed stirring for emulsification.

[0164] Optionally, analyzing the emulsification effect of the emulsified solution comprises:

[0165] measuring the dynamic viscosity of the emulsified solution;

[0166] Determining the temperature of the emulsified solution corresponding to the emulsification environment;

[0167] extracting spherical particles from the emulsified solution and measuring particle diameters of the spherical particles;

[0168] According to the dynamic viscosity, temperature and particle diameter, the particle diffusion coefficient of the emulsified solution is calculated using the following formula:

[0169]

[0170] Among them, θ represents the particle diffusion coefficient, and ρ represents the Boltzmann constant, which is approximately 1.38×10 -23 Joule per Kelvin, W d represents temperature, π represents circumference, L represents particle diameter, and μ represents dynamic viscosity;

[0171] Determining the particle distribution of the emulsified solution based on the particle diffusion coefficient;

[0172] The emulsification stability of the emulsified solution is analyzed, and the emulsification effect of the emulsified solution is determined based on the emulsification stability and particle distribution.

[0173] The dynamic viscosity refers to the measure of the internal friction of the emulsified solution when it flows. The spherical particles refer to particles of the water-in-oil colostrum that have an approximately spherical shape. The particle diffusion coefficient is a physical quantity that describes the diffusion rate of the water-in-oil colostrum particles in the emulsified solution.

[0174] Optionally, the extraction of the emulsified solution can be carried out by centrifugation, filtration, etc.

[0175] The embodiment of the present invention can improve the stability of the double emulsion and prevent problems such as stratification, flocculation and demulsification by determining the external water phase of the water-in-oil colostrum. The external water phase refers to the outermost layer, which is the water phase surrounding the oil phase and contains emulsifiers, stabilizers, electrolytes and other ingredients.

[0176] Optionally, the determination of the external water phase of the water-in-oil colostrum can be confirmed by a microstructure analysis method, wherein the microstructure analysis refers to the use of a series of technical means to study and describe the structural characteristics of materials at a microscopic scale.

[0177] Furthermore, the embodiment of the present invention can reduce the direct contact of drugs with certain tissues and improve the taste of oral liquid by constructing the water-in-oil-in-water emulsion of the water-in-oil colostrum based on the external water phase. The water-in-oil-in-water emulsion refers to an emulsion system with a special structure, which is composed of three different phases, namely, an internal water phase, an oil phase and an external water phase.

[0178] As an embodiment of the present invention, the water-in-oil-in-water emulsion of the water-in-oil colostrum is constructed based on the external water phase, comprising:

[0179] A stabilizer is provided for secondary emulsification of the water-in-oil colostrum and the external aqueous phase;

[0180] Based on the stabilizer, the water-in-oil colostrum and the external aqueous phase are secondary emulsified using a preset emulsification technology to obtain a double-emulsified solution;

[0181] Analyzing the particle encapsulation efficiency and drug release behavior of the emulsified solution;

[0182] Determining the emulsification performance of the emulsified solution based on the particle encapsulation efficiency and drug release behavior;

[0183] When the emulsion performance reaches the preset emulsion performance standard, the emulsion solution is extracted to obtain the water-in-oil-in-water emulsion.

[0184] Among them, the stabilizer refers to a class of additives used to improve the stability of emulsions, such as surfactants, polymers, inorganic salts, etc. The emulsified solution refers to a mixed solution containing water-in-oil-in-water emulsion obtained by a secondary emulsification process. The particle encapsulation efficiency refers to the ratio between the amount of drug encapsulated in the emulsion droplets and the total amount of drug fed. The drug release behavior refers to the process and rate of drug release from the emulsion to the external medium (usually body fluids). The emulsion performance refers to the behavior and characteristics of the emulsified solution under specific conditions, such as: particle size distribution, stability, microstructure, etc. The preset performance standard refers to that set according to the intended application of the emulsion, for example, a drug delivery emulsion may require a specific release rate, stability and biocompatibility.

[0185] S5, constructing a solidification environment for the water-in-oil-in-water emulsion, solidifying the water-in-oil-in-water emulsion based on the solidification environment to obtain a microcapsule-external aqueous phase mixture, separating the microcapsule-external aqueous phase mixture to obtain drug component microcapsules, mixing the adsorbed oral liquid and the drug component microcapsules to obtain a target oral liquid.

[0186] The embodiment of the present invention can solidify the oil phase in the water-in-oil-in-water emulsion to form a microcapsule structure by constructing the solidification environment of the water-in-oil-in-water emulsion. The solidification environment refers to a specific set of conditions, which are used to promote and realize the process of the oil phase in the water-in-oil-in-water emulsion or the entire emulsion system from liquid to solid. For example: temperature, pH value, chemical crosslinking agent, pressure, etc.

[0187] In the embodiment of the present invention, the water-in-oil-in-water emulsion is solidified based on the solidification environment to obtain a microcapsule-external aqueous phase mixture, which can facilitate the subsequent purification and formulation process. The microcapsule-external aqueous phase mixture refers to a mixture of microcapsules and external aqueous phase formed by solidifying the water-in-oil-in-water emulsion.

[0188] Optionally, based on the solidification environment, the water-in-oil-in-water emulsion is solidified to obtain a microcapsule-external aqueous phase mixture which can be solidified by a vacuum freeze-drying method.

[0189] In the embodiment of the present invention, the drug component microcapsules are obtained by separating the microcapsule-external aqueous phase mixture, which can avoid direct contact between the drug component and the taste buds and improve the taste of the oral liquid. The drug component microcapsule refers to a drug microcapsule that wraps the drug component inside the microcapsule.

[0190] Optionally, the separation of the microcapsule-external aqueous phase mixture to obtain the drug component microcapsules can be carried out by chromatographic separation, wherein the chromatographic separation refers to the use of different distribution coefficients of different components in the stationary phase and the mobile phase to achieve separation through the flow of the eluent.

[0191] In the embodiment of the present invention, the oral liquid after adsorption and the microcapsules of drug components are mixed to obtain the target oral liquid, which can improve the taste of the final product and make it easier for the target users to accept. The oral liquid after adsorption refers to the solution after the drug components are extracted, and the target oral liquid refers to the oral liquid that meets the taste requirements of the target users.

[0192] The embodiment of the present invention can adjust the taste of the oral liquid in a customized manner by obtaining the oral liquid required by the target user and the taste requirements of the target user, thereby improving the user's usage experience and satisfaction; optionally, the embodiment of the present invention can more accurately evaluate and adjust the content of the bitter component by determining the bitterness value corresponding to the bitter component based on the taste analysis model to achieve the best taste balance; the embodiment of the present invention can significantly reduce the bitterness in the oral liquid by using the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the amount of resin added, thereby improving the taste of the product and the compliance of the target user; the embodiment of the present invention can reduce the degradation and inactivation of the drug component and improve the stability of the drug by mixing the carrier material and the drug component based on the optimal mixing ratio to obtain a drug-carrier mixture; the embodiment of the present invention can improve the stability of the emulsion by determining the external water phase of the oil-in-water colostrum, and prevent problems such as stratification, flocculation and demulsification. Finally, the embodiment of the present invention can improve the taste of the final product by mixing the adsorbed oral liquid with the drug component microcapsules to obtain the target oral liquid, making it easier for the target user to accept. Therefore, the present invention can improve the taste of oral liquid medicine.

[0193] like Figure 2 1 is a functional module diagram of a control system for the taste of oral liquid medicine provided by an embodiment of the present invention.

[0194] The control system 200 for the taste of oral liquid medicine of the present invention can be installed in an electronic device. According to the functions to be implemented, the control system 200 for the taste of oral liquid medicine can include a bitterness analysis module 201, a bitterness adsorption module 202, a drug carrier mixing module 203, a drug carrier emulsification module 204 and a target oral liquid preparation module 205. The module of the present invention can also be referred to as a unit, which refers to a series of computer program segments that can be executed by an electronic device processor and can complete fixed functions, which are stored in the memory of the electronic device.

[0195] In this embodiment, the functions of each module / unit are as follows:

[0196] The bitterness analysis module 201 is used for the bitterness analysis module, which is used to obtain the oral liquid required by the target user and the taste requirements of the target user, identify the bitter components of the oral liquid, determine the bitter component content of the bitter components, build a taste analysis model of the oral liquid based on the bitter component content and taste requirements, and determine the bitterness value corresponding to the bitter component based on the taste analysis model;

[0197] The bitter adsorption module 202 is used to analyze the bitter chemical properties of the bitter component, determine the ion exchange resin used to adsorb the bitter component based on the bitter chemical properties, calculate the resin dosage of the oral liquid based on the bitter component content, and use the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the resin dosage to obtain the oral liquid after adsorption;

[0198] The drug-carrier mixing module 203 is used to extract the target component from the oral liquid after adsorption to obtain the drug component, determine the carrier material of the drug component, and calculate the optimal mixing ratio of the drug component and the carrier material, and mix the carrier material and the drug component based on the optimal mixing ratio to obtain a drug-carrier mixture;

[0199] The drug carrier emulsification module 204 is used to identify the oil phase of the drug-carrier mixture, emulsify the drug-carrier mixture and the oil phase to obtain water-in-oil colostrum, determine the external water phase of the water-in-oil colostrum, and construct a water-in-oil-in-water emulsion of the water-in-oil colostrum based on the external water phase;

[0200] The target oral liquid preparation module 205 is used to construct a solidification environment for the water-in-oil-in-water emulsion, solidify the water-in-oil-in-water emulsion based on the solidification environment to obtain a microcapsule-external aqueous phase mixture, separate the microcapsule-external aqueous phase mixture to obtain drug component microcapsules, and mix the adsorbed oral liquid and the drug component microcapsules to obtain the target oral liquid.

[0201] An embodiment of the present invention provides an electronic device for implementing a method for controlling the taste of oral liquid medicine.

Claims

1. A method for controlling the taste of an oral liquid medicine, characterized in that: The method comprises: Obtaining the oral liquid required by the target user and the taste requirements of the target user, identifying the bitter component of the oral liquid, determining the bitter component content of the bitter component, constructing a taste analysis model of the oral liquid based on the bitter component content and the taste requirements, and determining the bitterness value corresponding to the bitter component based on the taste analysis model; Analyze the bitter chemical properties of the bitter component, determine the ion exchange resin used to adsorb the bitter component based on the bitter chemical properties, calculate the amount of resin added to the oral liquid using the bitter component content, and use the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the amount of resin added to obtain the adsorbed oral liquid; Extracting target components from the oral liquid after adsorption to obtain drug components, determining carrier materials for the drug components, and calculating an optimal mixing ratio of the drug components and the carrier materials, and mixing the carrier materials and the drug components based on the optimal mixing ratio to obtain a drug-carrier mixture; Identifying the oil phase of the drug-carrier mixture, emulsifying the drug-carrier mixture and the oil phase to obtain a water-in-oil colostrum, determining the external water phase of the water-in-oil colostrum, and constructing a water-in-oil-in-water multiple emulsion of the water-in-oil colostrum based on the external water phase; A solidification environment of the water-in-oil-in-water emulsion is constructed, and based on the solidification environment, the water-in-oil-in-water emulsion is solidified to obtain a microcapsule-external aqueous phase mixture, the microcapsule-external aqueous phase mixture is separated to obtain drug component microcapsules, and the adsorbed oral liquid and the drug component microcapsules are mixed to obtain a target oral liquid.

2. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The method of constructing a taste analysis model of the oral liquid based on the bitter component content and taste requirements includes: Based on the taste requirement, analyzing the taste value of the oral liquid; constructing an initial taste analysis model of the oral liquid according to the bitter component content and the taste value; Acquiring experimental data of the initial taste analysis model, and training the taste analysis model based on the experimental data to obtain a trained taste analysis model; The F1 score of the training taste analysis model is calculated, and when the F1 score meets a preset F1 score standard, the training taste analysis model is used as a taste analysis model.

3. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The method of determining the ion exchange resin for adsorbing the bitter component based on the bitter chemical properties includes: Based on the bitter chemical properties, identifying the bitter functional group of the bitter component; determining a resin functional group for adsorbing the bitter functional group; Determining the multiple ion exchange resins used for adsorbing the bitter components by means of the resin functional groups; Testing the plurality of ion exchange resins to obtain exchange test results; Analyzing resin test parameters of the plurality of ion exchange resins according to the exchange test results, wherein the resin test parameters include: exchange capacity, adsorption rate, and adsorption selectivity; Analyzing the cost performance of the plurality of ion exchange resins based on the resin test parameters; According to the cost performance ratio, an ion exchange resin of the plurality of ion exchange resins is determined.

4. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The method of calculating the amount of resin added to the oral liquid using the bitter component content includes: Determining the adsorption environment of the oral liquid, wherein the adsorption environment includes: temperature, stirring time and stirring speed; measuring the oral liquid volume of the oral liquid; Based on the adsorption environment, analyzing the adsorption amount of the oral liquid corresponding to the ion exchange resin; The amount of resin added to the oral liquid is calculated according to the adsorption amount, the volume of the oral liquid and the bitter component content.

5. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The carrier material for determining the drug component comprises: Analyzing the pharmacochemical properties and pharmacophysical properties of the drug ingredients; determining the release time and release pattern of the drug component; Determine the candidate carrier material of the drug component according to the drug chemical properties, drug physical properties, release time and release pattern; identifying material properties of the candidate support material; Testing the drug component and the candidate carrier material to obtain a drug-carrier mixture test result; Based on the drug-carrier mixing test results, analyzing the influence of the candidate carrier material on the drug component; Determine the stability and release behavior of the drug component in the candidate carrier material through the drug-carrier mixing test results; The optimal carrier material among the candidate carrier materials is determined based on the characteristics, influence, stability and release behavior of the carrier material.

6. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The method of mixing the carrier material and the drug component based on the optimal mixing ratio to obtain a drug-carrier mixture comprises: measuring a pharmaceutical ingredient mass of the pharmaceutical ingredient; configuring a carrier material mass of the carrier material based on the optimal mixing ratio; Based on the mass of the drug component and the mass of the carrier material, the drug component and the carrier material are mixed by a preset mechanical stirring method to obtain an initial drug-carrier mixture; Detecting the mixture quality of the initial drug-carrier mixture, wherein the mixture quality includes: mixture stability and mixture uniformity; When the quality of the mixture meets the preset quality standard, the initial drug-carrier mixture is used as a drug-carrier mixture.

7. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The method of emulsifying the drug-carrier mixture and the oil phase to obtain water-in-oil colostrum comprises: dissolving the drug-carrier mixture to obtain a mixture aqueous phase; Constructing an emulsified environment of the water phase and the oil phase of the mixture, wherein the emulsified environment includes: emulsification temperature, emulsification time and emulsification stirring rate; An emulsifier is provided for configuring the aqueous phase and the oil phase of the mixture; According to the emulsification environment, the aqueous phase and the oil phase of the mixture are emulsified using the emulsifier to obtain an emulsified solution; analyzing the emulsification effect of the emulsified solution; When the emulsification effect meets the preset emulsification effect standard, the emulsified solution is extracted to obtain water-in-oil colostrum.

8. The method for controlling the mouthfeel of oral liquid medicine according to claim 7, characterized in that: The analyzing the emulsification effect of the emulsified solution comprises: measuring the dynamic viscosity of the emulsified solution; Determining the temperature of the emulsified solution corresponding to the emulsification environment; extracting spherical particles from the emulsified solution and measuring particle diameters of the spherical particles; Calculating the particle diffusion coefficient of the emulsified solution according to the dynamic viscosity, temperature and particle diameter; Determining the particle distribution of the emulsified solution based on the particle diffusion coefficient; The emulsification stability of the emulsified solution is analyzed, and the emulsification effect of the emulsified solution is determined based on the emulsification stability and particle distribution.

9. The method for controlling the mouthfeel of oral liquid medicine according to claim 1, characterized in that: The water-in-oil-in-water emulsion of the water-in-oil colostrum is constructed based on the external water phase, comprising: A stabilizer is provided for secondary emulsification of the water-in-oil colostrum and the external aqueous phase; Based on the stabilizer, the water-in-oil colostrum and the external aqueous phase are secondary emulsified using a preset emulsification technology to obtain a double-emulsified solution; Analyzing the particle encapsulation efficiency and drug release behavior of the emulsified solution; Determining the emulsification performance of the emulsified solution based on the particle encapsulation efficiency and drug release behavior; When the emulsion performance reaches the preset emulsion performance standard, the emulsion solution is extracted to obtain the water-in-oil-in-water emulsion.

10. A control system for the taste of oral liquid medicine, characterized in that: A method for controlling the taste of an oral liquid medicine according to any one of claims 1 to 9, the system comprising: A bitterness analysis module, used to obtain the oral liquid required by the target user and the taste requirements of the target user, identify the bitter components of the oral liquid, determine the bitter component content of the bitter components, construct a taste analysis model of the oral liquid based on the bitter component content and taste requirements, and determine the bitterness value corresponding to the bitter component based on the taste analysis model; A bitter adsorption module, used for analyzing the bitter chemical properties of the bitter component, determining the ion exchange resin used to adsorb the bitter component based on the bitter chemical properties, calculating the amount of resin added to the oral liquid using the bitter component content, and using the ion exchange resin to adsorb the bitterness of the oral liquid based on the bitterness value and the amount of resin added to obtain the adsorbed oral liquid; A drug-carrier mixing module, used for extracting target components from the oral liquid after adsorption to obtain drug components, determining carrier materials for the drug components, and calculating an optimal mixing ratio of the drug components and the carrier materials, and mixing the carrier materials and the drug components based on the optimal mixing ratio to obtain a drug-carrier mixture; a drug carrier emulsification module, for identifying the oil phase of the drug-carrier mixture, emulsifying the drug-carrier mixture and the oil phase to obtain a water-in-oil colostrum, determining the external water phase of the water-in-oil colostrum, and constructing a water-in-oil-in-water multiple emulsion of the water-in-oil colostrum based on the external water phase; The target oral liquid preparation module is used to construct a solidification environment for the water-in-oil-in-water emulsion, solidify the water-in-oil-in-water emulsion based on the solidification environment to obtain a microcapsule-external aqueous phase mixture, separate the microcapsule-external aqueous phase mixture to obtain drug component microcapsules, and mix the adsorbed oral liquid and the drug component microcapsules to obtain the target oral liquid.

Images